Pallave Dasari

Dr. Pallave Dasari

The University of Adelaide, Adelaide, Australia
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2005 in Cellular Immunology
Verified
Journal Article
Closed access
PDPallave Dasari
Pallave Dasari
INIan C. Nicholson
Ian C. Nicholson
GHGreg Hodge
Greg Hodge
GDGeoffrey W. Dandie
Geoffrey W. Dandie
HZHeddy Zola
Heddy Zola

4 July 2014 in Journal of Mammary Gland Biology and Neoplasia
Verified
Journal Article
Closed access
PDF file
ENEleanor F. Need
Eleanor F. Need
VAVahid Atashgaran
Vahid Atashgaran
Wendy IngmanWendy Ingman
Wendy Ingman
PDPallave Dasari
Pallave Dasari

1 June 2021 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
AGAmita G. Ghadge
Amita G. Ghadge
PDPallave Dasari
Pallave Dasari
JSJennifer Stone
Jennifer Stone
ETErik W. Thompson
Erik W. Thompson
RRRebecca L. Robker
Rebecca L. Robker
Wendy IngmanWendy Ingman
Wendy Ingman

27 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MAMaddison Archer
Maddison Archer
PDPallave Dasari
Pallave Dasari
AEAndreas Evdokiou
Andreas Evdokiou
Wendy IngmanWendy Ingman
Wendy Ingman
Mammographic density is an important risk factor for breast cancer; women with extremely dense breasts have a four to six fold increased risk of breast cancer compared to women with mostly fatty breasts, when matched with age and body mass index. High mammographic density is characterised by high proportions of stroma, containing fibroblasts, collagen and immune cells that suggest a pro-tumour inflammatory microenvironment. However, the biological mechanisms that drive increased mammographic density and the associated increased risk of breast cancer are not yet understood. Inflammatory factors such as monocyte chemotactic protein 1, peroxidase enzymes, transforming growth factor beta, and tumour necrosis factor alpha have been implicated in breast development as well as breast cancer risk, and also influence functions of stromal fibroblasts. Here, the current knowledge and understanding of the underlying biological mechanisms that lead to high mammographic density and the associated increased risk of breast cancer are reviewed, with particular consideration to potential immune factors that may contribute to this process.

Verified
Journal Article
Open access
PDF file
MAMaddison Archer
Maddison Archer
SBSarah M Bernhardt
Sarah M Bernhardt
LHLeigh Hodson
Leigh Hodson
LWLucy Woolford
Lucy Woolford
MHMark Van der Hoek
Mark Van der Hoek
Wendy IngmanWendy Ingman
Wendy Ingman
CCL2 is an inflammatory cytokine that regulates macrophage activity and is implicated in increased mammographic density and early breast tumorigenesis. The role of CCL2 in mediating stromal interactions that contribute to breast tumorigenesis has yet to be fully elucidated. THP-1-derived macrophages and mammary fibroblasts were co-cultured for 72 h. Fibroblasts and macrophages were analysed for phenotype, expression of inflammatory and ECM-regulatory genes and collagen production. Mice overexpressing CCL2 in the mammary glands were analysed for global gene expression by RNAseq at 12 weeks of age. These mice were cross-bred with PyMT mammary tumour mice to examine the role of CCL2 in tumorigenesis. The co-culture of macrophages with fibroblasts resulted in macrophage polarization towards an M2 phenotype, and upregulated expression of CCL2 and other genes associated with inflammation and ECM remodelling. CCL2 increased the production of insoluble collagen by fibroblasts. A global gene expression analysis of CCL2 overexpressing mice revealed that CCL2 upregulates cancer-associated gene pathways and downregulates fatty acid metabolism gene pathways. In the PyMT mammary tumour model, CCL2 overexpressing mice exhibited increased macrophage infiltration and early tumorigenesis. Interactions between macrophages and fibroblasts regulated by CCL2 can promote an environment that may increase breast cancer risk, leading to enhanced early tumorigenesis.

Verified
Journal Article
Open access
PDF file
Wendy IngmanWendy Ingman
Wendy Ingman
BRBernadette Richards
Bernadette Richards
JSJackie Mary Street
Jackie Mary Street
DCDrew Carter
Drew Carter
MRMary Rickard
Mary Rickard
PDPallave Dasari
Pallave Dasari
Breast density, also known as mammographic density, refers to white and bright regions on a mammogram. Breast density can only be assessed by mammogram and is not related to how breasts look or feel. Therefore, women will only know their breast density if they are notified by the radiologist when they have a mammogram. Breast density affects a woman’s breast cancer risk and the sensitivity of a screening mammogram to detect cancer. Currently, the position of BreastScreen Australia and the Royal Australian and New Zealand College of Radiologists is to not notify women if they have dense breasts. However, patient advocacy organisations are lobbying for policy change. Whether or not to notify women of their breast density is a complex issue and can be framed within the context of both public health ethics and clinical ethics. Central ethical themes associated with breast density notification are equitable care, patient autonomy in decision-making, trust in health professionals, duty of care by the physician, and uncertainties around evidence relating to measurement and clinical management pathways for women with dense breasts. Legal guidance on this issue must be gained from broad legal principles found in the law of negligence and the test of materiality. We conclude a rigid legal framework for breast density notification in Australia would not be appropriate. Instead, a policy framework should be developed through engagement with all stakeholders to understand and take account of multiple perspectives and the values at stake.